Among 88 children with CML-CP, 57 (64.8%) had a 3-month BCR::ABL1 assessment; the median 3-month BCR::ABL1 level was 3.55% (range, 2.88–114.24%). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.